Cocrystal Pharma (COCP) Non Operating Interest Expenses (2010 - 2026)
Cocrystal Pharma's (COCP) quarterly Non Operating Interest Expenses came in at -$10000.0 in Q2 2026, up 64.29% year-over-year from -$6087.0 in Q2 2025, and up 54.55% quarter-over-quarter from -$22000.0 in Q1 2026.
Powered by 
Analysis
Cocrystal Pharma (COCP) Non Operating Interest Expenses (2010 - 2026) Analysis & Trends
Cocrystal Pharma has disclosed Non Operating Interest Expenses across 13 years of filings, most recently posting -$10000.0 for Q2 2026.
- In Q2 2026, Non Operating Interest Expenses rose 64.29% year-over-year to -$10000.0; the TTM figure through Jun 2026 stood at -$101000.0 (up 56.28% YoY), while the FY2025 annual figure was -$134000.0, up 75.05% from the prior year.
- Non Operating Interest Expenses came in at -$10000.0 for Q2 2026 at Cocrystal Pharma, up from -$22000.0 in the prior quarter.
- In the past five years, Non Operating Interest Expenses ranged from a high of $1000.0 in Q1 2022 to a low of -$320000.0 in Q3 2023.
- Average Non Operating Interest Expenses over 5 years is -$89400.0, with a median of -$47000.0 recorded in 2025.
- Year-over-year, Non Operating Interest Expenses tumbled 32100.0% in 2023 and soared 83.18% in 2025.
- Over 5 years, Non Operating Interest Expenses stood at $1000.0 in 2022, then tumbled by 18100.0% to -$180000.0 in 2023, then jumped by 69.44% to -$55000.0 in 2024, then grew by 14.55% to -$47000.0 in 2025, then jumped by 78.72% to -$10000.0 in 2026.
- Per Business Quant data, the three most recent Non Operating Interest Expenses figures were -$10000.0 in Q2 2026, -$22000.0 in Q1 2026, and -$47000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 673.00 Mn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 247.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 11.00 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | -1.00 Mn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Cocrystal Pharma | 16.82 Mn | 14.50 Mn | - | -10,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -10,000.00 |
| Mar 31, 2026 | -22,000.00 |
| Dec 31, 2025 | -47,000.00 |
| Sep 30, 2025 | -22,000.00 |
| Jun 30, 2025 | -28,000.00 |
| Mar 31, 2025 | -37,000.00 |
| Dec 31, 2024 | -55,000.00 |
| Sep 30, 2024 | -111,000.00 |
| Jun 30, 2024 | -151,000.00 |
| Mar 31, 2024 | -220,000.00 |
| Dec 31, 2023 | -180,000.00 |
| Sep 30, 2023 | -320,000.00 |
| Jun 30, 2023 | -140,000.00 |
| Sep 30, 2022 | 1,000.00 |
| Mar 31, 2022 | 1,000.00 |
| Sep 30, 2021 | 1,000.00 |
| Jun 30, 2021 | 2,000.00 |
| Mar 31, 2021 | 1,000.00 |
| Dec 31, 2020 | 2,000.00 |
| Sep 30, 2020 | 2,000.00 |